<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04039529</url>
  </required_header>
  <id_info>
    <org_study_id>TUH SCENERGY</org_study_id>
    <nct_id>NCT04039529</nct_id>
  </id_info>
  <brief_title>Novel Guidance Device for Image Fusion and Needle Guidance in Lung, Liver or Kidney Biopsy</brief_title>
  <official_title>Novel Guidance Device for Image Fusion and Needle Guidance in Lung, Liver or Kidney Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clear Guide Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Temple University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Clear Guide Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether a new image fusion technology can reduce patient radiation
      dose from CTs and/or procedure time during biopsies of lung, liver or kidney.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study proposes the use of a new fusion technology, Scenergy (Clear Guide Medical; FDA
      510(k) K171677), which fuses CT images to real-time US images to minimize the drawbacks of
      each modality while enhancing their benefits. Such benefits include, the reduction of
      radiation dose to the patient with the fusion of initial CT imaging overlaying the live US
      images. The fused imaging software allows the operator to watch the needle tip advance
      towards the lesion on both live US and overlaid CT imaging. In such a setting, the operator
      would only need to perform an initial CT scan, advance the needle into position using fused
      US/CT images, and a final CT scan to ensure needle tip location. This eliminates interval CT
      scans that are usually required after each incremental needle position adjustment, and thus,
      reduces radiation dose to the patient and wasted procedural time during the incremental CT
      scans.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>testing whether biopsies and ablations performed with the SCENERGY result in less patient radiation dose or reduced procedure time compared to biopsies performed under CT-guidance only.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Masking is impossible due to the hardware that is present when using the SCENERGY</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Radiation Dose during Procedure</measure>
    <time_frame>1 hour</time_frame>
    <description>The number of CTs or Fluoroscopy shots during the biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Target of Biopsy</measure>
    <time_frame>1 hour</time_frame>
    <description>The amount of time in seconds that the physician takes to reach the target of biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experience Level</measure>
    <time_frame>1 hour</time_frame>
    <description>Number of years physician has practiced in Interventional Radiology</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Liver Biopsy</condition>
  <condition>Lung Biopsy</condition>
  <condition>Kidney Biopsy</condition>
  <arm_group>
    <arm_group_label>CT-only guided biopsy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The current standard of care for biopsy at Temple University Hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCENERGY-guided Biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The use of the SCENERGY to fuse CT and Ultrasound for biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SCENERGY-guided Biopsy</intervention_name>
    <description>Use of SCENERGY during a lung, liver or kidney biopsy</description>
    <arm_group_label>SCENERGY-guided Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients between the ages of 18 and 80 years old at time of procedure who are
             pre-scheduled for a lung, kidney, or liver biopsy.

        Exclusion Criteria:

          -  any patient who was under the age of 18 or over the age of 80 at time of the procedure
             or who does not wish to volunteer for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dorothee Heisenberg, PhD</last_name>
    <phone>4435703835</phone>
    <email>heisenberg@clearguidemedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Cohen, MD</last_name>
      <phone>215-707-3390</phone>
      <email>gary.cohen@tuhs.temple.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung biopsy</keyword>
  <keyword>kidney biopsy</keyword>
  <keyword>liver biopsy</keyword>
  <keyword>image fusion</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

